Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased ...

For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news.

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with ...

The new drug would add another oral GLP-1 with no fasting or fluid intake restrictions to clinicians’ toolboxes, improving options for targeted treatment.

Compared with nonusers, those on a GLP-1 receptor agonist had fewer thromboembolic events and higher survival.

Real-world data found patients on GLP-1s had lower odds of osteomyelitis, ulcers, and ampu ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

GLP-1 receptor agonist drugs, used for the treatment of diabetes—and more recently, weight loss—are associated with a ...

For patients with knee osteoarthritis (OA), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a ...

Foundayo was incredibly effective at lowering A1C, which is a metric doctors use to measure average blood sugar levels over a ...

For adults with obesity but without diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a ...

Metastatic progression reduction is associated with GLP-1 RA initiation after cancer diagnosis across multiple solid tumors.